Horm Metab Res
DOI: 10.1055/a-2281-0911
Original Article: Endocrine Care
1
Medicine, “Carol Davila” University of Medicine and Pharmacy,
Bucharest, Romania
2
Endocrinology IV, “C.I. Parhon” National Institute of Endocrinology,
Bucharest, Romania
,
Oana Pop
1
Medicine, “Carol Davila” University of Medicine and Pharmacy,
Bucharest, Romania
,
Mariana Purice
3
Research Department, “C.I. Parhon” National Institute of Endocrinology,
Bucharest, Romania
,
Corin Badiu
1
Medicine, “Carol Davila” University of Medicine and Pharmacy,
Bucharest, Romania
2
Endocrinology IV, “C.I. Parhon” National Institute of Endocrinology,
Bucharest, Romania
› Author Affiliations
Funding Information
European Social Fund Plus — http://dx.doi.org/10.13039/501100004895;
POCU/993/6/13/154722
› Further Information
Also available at
![SFX Search]()
Buy Article Permissions and Reprints
Abstract
The aim was to compare the lipid profile of patients with GD treated with
anti-thyroid drugs (ATDs) using a titration regimen versus a block and replace
regimen. This is an 18-month prospective observational study. In this study were
included 149 medically treated GD patients, aged+>+18 years. Pregnant women
and patients treated with radioactive iodine therapy or partial/total
thyroidectomy were excluded. Patients were divided into 2 subgroups: titration
(A) and block and replace (B) therapy, according to the ATD regimen used.
Thyroid and metabolic profile was measured at baseline and at least one visit
during medical treatment. The whole group included 122 (81.87%) females (F) and
27 (18.12%) males (M), ratio F:M=4.5:1. As expected, at the time of diagnosis,
thyrotoxic patients were with normal lipid profile. During medical treatment, in
patients who achieved euthyroidism, the cholesterol levels increased as follows:
in subgroup A: by 52.9 mg/dl (95% CI: 26.4–79.3), p<0.001 for total
cholesterol (T-C), by 33.3 mg/dl (95% CI: 10.3–56.3), p=0.007 for low-density
lipoprotein cholesterol (LDL-C) and by 11.44 mg/dl (95% CI: 3.08–19.79), p=0.009
for high-density lipoprotein cholesterol (HDL-C); in subgroup B T-C increased by
45.1 mg/dl (95% CI: 22.2–68), p<0.001 and for LDL-C by 33.57 mg/dl (95% CI:
12.72–54.42), p=0.003. No statistically significant increase in triglyceride
levels was determined. Medical treatment of hyperthyroidism due to Graves’
disease increased cholesterol levels regardless of the ATD regimen used.
Keywords
hyperthyroidism -
cholesterol -
block-replace -
titration -
Graves’ disease
Publication History
Received: 04 December 2023
Accepted after revision: 27 February 2024
Article published online:
02 April 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart,
Germany
References
1
Ross DS,
Burch HB,
Cooper DS.
et al.
2016 American thyroid association guidelines for diagnosis and management of
hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26: 1343-1421
2
Bartalena L.
Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 2013; 9: 724-734
3
Sharma M,
Modi A,
Goyal M.
et al.
Anti-thyroid antibodies and the gonadotrophins profile (LH/FSH) in euthyroid
polycystic ovarian syndrome women. Acta Endocrinol (Buchar) 2022; 18: 79-85
4
Genc GC,
Celik SK,
Arpaci D.
et al.
Granulysin peptide and gene polymorphism in the pathogenesis of Hashimoto
thyroiditis. Acta Endocrinol (Buchar) 2022; 18: 288-293
5
Chen Y,
Wu X,
Wu R.
et al.
Changes in profile of lipids and adipokines in patients with newly diagnosed
hypothyroidism and hyperthyroidism. Sci Rep 2016; 6: 1-7
6
Abrams JJ,
Grundy SM.
Cholesterol metabolism in hypothyroidism and hyperthyroidism in man. J Lipid Res 1981; 22: 323-338
7
Senese R,
Cioffi F,
Petito G.
et al.
Thyroid hormone metabolites and analogues. Endocrine 2019; 66: 105-114
8
Senese R,
Lasala P,
Leanza C.
et al.
New avenues for regulation of lipid metabolism by thyroid hormones and
analogs. Front Physiol 2014; 5: 1-7
9
Bartalena L.
Hyperthyroidism due to Graves’ disease – is there an optimal pharmacological
treatment regimen?. Eur Endocrinol 2008; 4: 63-65
10
Hashizume K,
Ichikawa K,
Sakurai A.
et al.
Administration of thyroxine in treated Graves’ disease – effects on the level of
464 antibodies to thyroid stimulating hormone receptors and on the risk of
recurrence of hyperthyroidism. N Engl J Med 1991; 324: 947-953
11
Masiello E,
Veronesi G,
Gallo D.
et al.
Antithyroid drug treatment for Graves’ disease: baseline predictive models of
relapse after treatment for a patient-tailored management. J Endocrinol Invest 2018; 41: 1425-1432
12
Abraham P,
Avenell A,
Park CM.
et al.
A systematic review of drug therapy for Graves’ hyperthyroidism. Eur J Endocrinol 2005; 153: 489-498
13
Vaidya B,
Wright A,
Shuttleworth J.
et al.
Block & replace regime versus titration regime of antithyroid drugs for the
treatment of Graves’ disease: A retrospective observational study. Clin Endocrinol (Oxf) 2014; 81: 610-613
14
Duntas LH.
Block-and-replace vs. titration antithyroid drug regimen for Graves’
hyperthyroidism: two is not always better than one. J Endocrinol Invest 2021; 44: 1337-1339
15
Duntas LH,
Brenta G.
The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am 2012; 96: 269-281
16
Kotwal A,
Cortes T,
Genere N.
et al.
Treatment of thyroid dysfunction and serum lipids: a systematic review and
meta-analysis. J Clin Endocrinol Metab 2020; 105: 3683-3694
17
Sauter G,
Weiss M,
Hoermann R.
Cholesterol 7 alpha-hydroxylase activity in hypothyroidism and 481
hyperthyroidism in humans. Horm Metab Res 1997; 29: 176-179
18
O’Brien T,
Katz K,
Hodge D.
et al.
The effect of the treatment of hypothyroidism and hyperthyroidism on plasma
lipids and apolipoproteins AI, AII and E. Clin Endocrinol (Oxf) 1997; 46: 17-20
19
Vrca VB,
Mayer L,
Škreb F.
et al.
Antioxidant supplementation and serum lipids in patients with Graves’ disease:
Effect on LDL-cholesterol. Acta Pharm 2012; 62: 115-122
20
Razvi S,
Vaidya B,
Perros P.
et al.
What is the evidence behind the evidence-base? The premature death of
block-replace antithyroid drug regimens for Graves’ disease. Eur J Endocrinol 2006; 154: 783-786
21
Boelaert K,
Edward Visser W,
Taylor PN.
et al.
Endocrinology in the time of COVID-19: management of hyperthyroidism and
hypothyroidism. Eur J Endocrinol 2020; 183: G33-G39
22
Francis N,
Francis T,
Lazarus JH.
et al.
Current controversies in the management of Graves’ hyperthyroidism. Expert Rev Endocrinol Metab 2020; 15: 159-169
23
Struja T,
Fehlberg H,
Kutz A.
et al.
Can we predict relapse in Graves’ disease? Results from a systematic review and
meta-analysis. Eur J Endocrinol 2017; 176: 87-97
24
Subekti I,
Pramono LA.
Current diagnosis and management of Graves’ disease. Acta Med Indones 2018; 50: 177-182
25
Struja T,
Kaeslin M,
Boesiger F.
et al.
External validation of the GREAT score to predict relapse risk in Graves’
disease: results from a multicenter, retrospective study with 741 patients. Eur J Endocrinol 2017; 176: 413-419
26
Effraimidis G.
Predictive scores in autoimmune thyroid disease: are they useful?. Eur J Endocrinol 2019; 181: R119-R131
27
Jiang X,
Hu H,
Fu Z.
et al.
Association between the ctla-4 exon 1+49a/G polymorphism and the relapse of
Grave’s disease after Atd withdrawal: a meta-analysis. Acta Endocrinol 2022; 18: 324-332
28
Bartalena L,
Burch HB,
Burman KD.
et al.
A 2013 European survey of clinical practice patterns in the management of
Graves’ disease. Clin Endocrinol (Oxf) 2016; 84: 115-120
29
Sabini E,
Mazzi B,
Profilo MA.
et al.
High serum cholesterol is a novel risk factor for Graves’ orbitopathy: results
of a cross-sectional study. Thyroid 2018; 28: 386-394
30
Lanzolla G,
Sabini E,
Profilo MA.
et al.
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a
confirmatory study. J Endocrinol Invest 2018; 41: 1417-1423
31
Lanzolla G,
Vannucchi G,
Ionni I.
et al.
Cholesterol serum levels and use of statins in Graves’ orbitopathy: a new
starting point for the therapy. Front Endocrinol (Lausanne) 2020; 10: 1-8
Comments (0)